Navigation Links
DIFICID™ Demonstrated Early Superiority in the First 12 Days Compared to Vancomycin in New Analysis of Phase 3 Study Results
Date:10/20/2011

s in patients within the first 12 days following initiation of treatment but also significantly reduced persistent diarrhea, disease recurrence or death through day 40 of the study."

The analysis was independently funded by the NIHR Biomedical Research Centre, Oxford, a research partnership between the Oxford Radcliffe Hospitals and the University of Oxford.

Study Methods

The analysis was performed using data from two prospective, randomized, double-blinded, non-inferiority Phase 3 studies evaluating DIFICID and oral vancomycin in the treatment of CDAD in adults 18 years of age or older. A non-inferiority design was utilized to demonstrate the efficacy of DIFICID (200 mg orally twice daily for 10 days) compared to vancomycin (125 mg orally four times daily for 10 days) in adults with CDAD. The studies enrolled a total of 1,164 adults with confirmed CDAD. The primary objective of both studies was to show that a 10-day course of DIFICID was as effective as oral vancomycin in achieving a clinical cure at the end of therapy. Clinical cure was defined as resolution of diarrhea (no more than 3 unformed stools for 2 consecutive days) maintained for the duration of therapy with no further requirement for therapy assessed two days after the end of the 10 day treatment. Subjects meeting the criteria for clinical cure were followed for 28 days after the end of treatment (36-40 days after randomization) and assessed for the additional efficacy endpoints of recurrence and global cure. Recurrence was defined by the reappearance of more than 3 unformed stools in any 24-hour period with C. difficile toxin A or B or both detected and a need for retreatment.  Global cure was defined as clinical cure without recurrence.  

To compile the results, researchers conducted a post-hoc exploratory analysis to determine the time-to-event for a composite endpoint of persistent diarrhea, disease recurrence or death of the combined intent-to-tre
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
2. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
3. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
4. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
5. Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
6. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
7. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
8. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
9. Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
10. Preclinical Studies in Pancreatic Cancer and Melanoma Demonstrated ADI-PEG 20 Works Synergistically With Inhibitors of Autophagy
11. Isis Pharmaceuticals Reports That Its Selective CRP Inhibitor Demonstrated Activity in a Phase 1 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
(Date:1/14/2014)... (Nasdaq: LMNX ) today announced that it expects ... Monday, February 3, 2014. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the fourth quarter and twelve months ended ...
(Date:1/14/2014)... 2014 Animal Emergency Critical Care, a LifeCentre partner practice, located ... is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is a well-seasoned ... Cole Taylor , are avid scuba divers. "As altitude skiers ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... 2012  Boston Scientific Corporation (NYSE: BSX ) ... Morgan Healthcare Conference in San Francisco. Hank ... the Company on Wednesday, January 11, 2012, beginning at ... Mahoney, President, and Jeff Capello, Executive Vice President and ...
... 2012  Mettler-Toledo International Inc. (NYSE: MTD ) today ... Healthcare Conference in San Francisco on Tuesday, January 10, 2012, ... hear a live webcast of the presentation, visit the investor ... .  A replay of the webcast will be available for ...
Cached Medicine Technology:Boston Scientific to Participate in 30th Annual J.P. Morgan Healthcare Conference 2
(Date:4/17/2014)... genetic variant specifically associated with the risk of ... per cent of all breast cancer cases. , ... sub-type, called invasive lobular carcinoma, gives researchers important ... kind of breast cancer, which can be missed ... in the journal PloS Genetics , was ...
(Date:4/17/2014)... Researchers at the University of California, San Diego School ... those who have suffered a recent major loss are ... older adults. , The study is published in this ... Psychiatry . , Because compassionate behaviors are associated with ... findings offer insights into ways to improve the outcomes ...
(Date:4/17/2014)... New Rochelle, NY, April 17, 2014U.S. military personnel ... "blast plus impact" concussive traumatic brain injury (TBI) ... were evacuated for other medical reasons. Differences in ... and depression 6-12 months after injury are reported ... , a peer-reviewed journal from Mary Ann Liebert, ...
(Date:4/17/2014)... 2014 By discovering a new mechanism that allows ... researchers at UC Irvine and the Salk Institute have ... or prevent stroke-induced brain damage. , A complex and ... death and primary reason for disability in the U.S. ... and lets blood-borne material into the brain, causing the ...
(Date:4/17/2014)... An international research team led by Cesar A. Arias, ... Center at Houston (UTHealth) has identified a new superbug ... The report appeared in the April 17 issue of ... The new superbug is part of a class of ... or MRSA, which is a major cause of hospital ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:New MRSA superbug emerges in Brazil 2
... 18 Nuvilex, Inc. (OTC Bulletin Board: NVLX), ... marketing initiatives designed to raise visibility of two of ... among the key 18 to 25 year old demographic ... 28th, expertly trained marketing and sales teams will be ...
... solutions provider ICW celebrates its opening in Canada ... Gingrich, Founder of the Center for Health Transformation and ... McKenna, Deputy Chair of TD Bank Financial Group and ... eHealth specialist InterComponentWare AG (ICW), will celebrate the launch ...
... highs , , WEDNESDAY, March 18 (HealthDay News) -- The number ... record level in the United States, and Cesarean delivery rates ... The total number of births, birth rate and proportion of ... 5 percent from 2006 to 2007. The estimated 1,714,643 babies ...
... announced that it has again received the World Wide ... Information Resource Center. Imaginis received a merit rating for ... period of Spring/Summer 2008. This is the fifth ... The WWW Health Awards program recognizes the best health ...
... Executive Search for Replacement is CompletedPlanned Investor Conference ... 4:15 PM ET LIVINGSTON, N.J., March 18 ... the recognized leader in advanced injection technologies, today ... will temporarily assume the post of Interim Chief ...
... Emphasis needed on improving policy, practice and personal skillsWASHINGTON, ... non-profit National Council on Aging (NCOA), with support from ... reveals a bleak and broken health care system for ... conditions. The results of the Re-Forming Health Care: ...
Cached Medicine News:Health News:Nuvilex, Inc. Launches Spring Break Initiatives Designed to Raise Visibility Among Key Demographic Group 2Health News:Nuvilex, Inc. Launches Spring Break Initiatives Designed to Raise Visibility Among Key Demographic Group 3Health News:Gingrich and McKenna to Speak on Transformation of Healthcare Delivery at ICW Launch 2Health News:Unmarried Childbirths in U.S. Reach Record Levels 2Health News:Milestone Scientific Announces Resignation of CEO 2Health News:Milestone Scientific Announces Resignation of CEO 3Health News:Video: NCOA Issues Call-to-Action for National Chronic Care Reform Based on Results of Comprehensive Survey of Americans with Chronic Conditions 2Health News:Video: NCOA Issues Call-to-Action for National Chronic Care Reform Based on Results of Comprehensive Survey of Americans with Chronic Conditions 3Health News:Video: NCOA Issues Call-to-Action for National Chronic Care Reform Based on Results of Comprehensive Survey of Americans with Chronic Conditions 4
The Nordt Knot Tightener allows both pushing and spreading of knots, reproducing identical techniques,used when tying traditional open knots. The Nordt Knot Tightener allows tying of any type of s...
Single step suture passage is made simple with Arthro-Pierce instruments. The low profile, highly sharpened tip allows easy passage through tissue in order to retrieve or apply suture....
12" suture passer...
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
Medicine Products: